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Abstract--Although, generally speaking, haematological malignancies are chemotherapy- 
responsive tumours and high remission induction rates are obtained, disease-related death is 
the rule rather than the exception. The appearance of cell populations, resistant o rnultidrug- 
based chemotherapy, constitutes the major problem to achieve cu resin these patients. Adva nces 
in cell biology have partly contributed to the elucidation of different multidrug resistance (MDR) 
mechanisms, which enable cells to survive the cytotoxic effects of multiple chemotherapeutic 
agents. Of these resistance mechanisms, the one that is referred to as classical MDR is the most 
extensively studied, both in the laboratory as well as in patients, and here we will focus on its 
clinical relevance in haematological malignancies. The classical MDR phenotype is caused by 
enhanced cellular drug efflux due to increased activity of a membrane-bound glycoprotein (P- 
glycoprotein) drug pump, that can pump out anthracyclines, anthracenediones, vinca alkaloids 
and epipodophyllotoxins, thereby actively lowering the intracellular drug concentrations to sub- 
lethal levels. As soon as molecular probes for the detection of MDR cells became available, 
clinical studies were initiated to answer three main questions. Do human turnout cells express 
P-glycoprotein? If so, is the expression indicative of a bad prognosis, c.q. resistant disease? And 
last but not least, can we interfere with the P-glycoprotein drug pump in the patient? Clinical data 
indicate that classical M DR may be involved in the development of drug resistance, especially in 
some haematological malignancies, such as acute myelocytic leukaemia (AML), non-Hodgkin's 
lymphomas (NHL), and multiple myelomas (MM). In almost all types of haematological malig- 
nancies, either untreated or treated, elevated P-glycoprotein levels have been reported, ranging 
from low to high. However, the acquisition of clinical MDR associated with P-glycoprotein 
expression occurs only in those diseases (for example, AML and M M) that are heavily treated with 
MDR-related drugs, probably by selection of pre-existing P-glycoprotein-expressing malignant 
cells. Since P-glycoprotein is found to be expressed on the membrane of normal haemopoietic 
progenitor cells as well, it seems likely that P-glycoprotein-positive haematological turnouts 
develop by malignant transformation of P-glycoprotein-expressing normal haemopoietic 
counterparts. Especially for AML, convincing data have been reported in the literature to show 
that P-glycoprotein expression at diagnosis is a bad prog nosticfactor that predicts refractoriness. 
Using in vitro model systems for classical MDR, a large number of agents have been identified 
that can circumvent P-glycoprotein-mediated rug resistance, the so-called resistance mod- 
ifying agents (RMA). Subsequently, clinical phase I and II studies have been initiated which 
combine the use of MDR-related drugs in conjunction with RMAs. The overall conclusions from 
such studies in AML, NHL, and MM are that modulation of drug resistance by RMAs seems 
promising and that further evaluation in prospective, randomized phase III trials is warranted. 
Key words: Multidrug resistance, MDR, P-glycoprotein, clinical relevance, haematological 
malignancies, circumvention of MDR, clinical trials. 
Introduction 
CHEMOTHERAPY FAILURE owing to cellular drug 
resistance r mains a major problem in most patients 
suffering from leukaemia, lymphoma or multiple 
myeloma. After an initial response, a relapse often 
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follows that neither esponds to the drugs initially 
used, nor to a variety of other anticancer drugs. 
Laboratory investigations have now provided acellu- 
lar basis for this clinically defined phenomenon of
pleiotropic drug resistance. Selection of cells in vitro 
for resistance to a 'naturally occurring' anticancer 
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drug, results in the development of cross-resistance 
to other, structurally unrelated rugs. Several human 
cell lines displaying such a multidrug resistance 
(MDR) phenotype have been identified, and so far 
three separate forms of MDR have been charac- 
terized in more detail: classical MDR, atypical MDR, 
and non-Pgp MDR. The classical MDR phenotype 
is caused by enhanced cellular drug efflux due to 
increased activity of a membrane-bound glycoprotein 
(P-glycoprotein) drug pump, that can pump out 
anthracyclines, anthracenediones, vinca alkaloids 
and epipodophyllotoxins, thereby actively lowering 
the intracellular drug concentrations to sublethal 
levels (for reviews on MDR, see refs [1 and 2]). A 
second form of pleiotropic drug resistance (atypical 
MDR) is associated with quantitative or qualitative 
alterations intopoisomerase II, a nuclear enzyme that 
actively participates in the lethal action of cytotoxic 
drugs [3]. Characteristically, there is cross-resistance 
to the full range of drugs that interact with the enzyme, 
among which are acridines, anthracyclines, anthra- 
cenediones, ellipticines and epipodophyllotoxins, but
not to the vinca alkaloids. The anti-topoisomerase II 
drugs are thought o exert their cytotoxic effects by 
formation of a stable ternary DNA-topoisomerase II 
drug complex. Because of the altered cross-resistance 
pattern, as compared with the classical MDR pheno- 
type, this form of drug resistance is referred to either 
as atypical MDR, or as altered topoisomerase II MDR 
(at-MDR), to denote the essential role of topo- 
isomerase II in this form of drug resistance. Atypical 
MDR cells do not overexpress P-glycoprotein, and are 
unaltered in their ability to accumulate drugs (for a 
review on atypical MDR, see ref. [4]). Although atypi- 
cal MDR is potentially of clinical importance, the 
question whether the phenomenon contributes to 
clinical drug resistance in haematological malignanc- 
ies cannot be answered yet, because so far only very 
limited data are available on the expression of topo- 
isomerase II in human tumour specimens [5-7]. The 
third form of MDR (non-Pgp MDR) strongly 
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resembles the classical MDR phenotype, as far as 
cross-resistance patterns are concerned, however, 
without expression of the P-glycoprotein molecule; 
hence the name non-Pgp-mediated MDR. Presum- 
ably there are different forms of non-Pgp MDR. In 
most non-Pgp MDR cells lines intracellular drug 
accumulation is reduced owing to energy-dependent, 
enhanced rug efflux [8-14], as in classical MDR. 
Recently, anew putative transmembrane drug trans- 
porter, called MDR-related protein (MRP) [15], has 
been identified in a non-Pgp MDR cell line that does 
not exhibit reduced intracellular drug accumulation 
[16] as the possible cause of drug resistance. However, 
MRP is found to be overexpressed in other non-Pgp 
MDR cell lines as well, irrespective of reduced intra- 
cellular drug accumulation [17]. Clearly, much work 
has to be done before the precise mechanisms under- 
lying non-Pgp MDR and the nature of the gene(s) 
affected are known. Of the above mentioned plei- 
otropic drug resistance phenotypes, the classical one 
is the most extensively studied, both in the laboratory 
and in cancer patients. Here we will restrict ourselves 
to review some clinical aspects of classical MDR. Since 
recent data indicate that classical MDR may be 
involved in the development of clinical drug resistance 
(for a review on the clinical relevance of MDR, see 
ref. [18]), especially in some haematological malig- 
nancies, we will focus on these diseases. 
As mentioned earlier, the classical MDR pheno- 
type is characterized bya reduced ability to accumu- 
late drugs, as compared with the parent cell lines, 
being most likely the main cause of multidrug resist- 
ance. This reduced drug accumulation is due to 
activity of an energy-dependent u idirectional drug 
efflux, pump wih broad substrate specificity. The 
MDR drug pump is composed of a transmembrane 
glycoprotein (P-glycoprotein) with a molecular 
weight of 170 kDa, encoded by tl~e so-called mdr 
genes, and uses energy in the form of ATP to trans- 
port drugs through a channel formed by the 
transmembrane s gments. In humans, two P-gly- 
coprotein isoforms (mdrl and mdr3) have been ident- 
ified [19, 20], of which, in transfection experiments, 
only the mdrl gene product (referred to as P-gly- 
coprotein) confers drug resistance [21, 22]. In classi- 
cal MDR cells, selection for resistance to 'naturally 
occurring" drugs, for example, anthracyclines, vinca 
alkaloids, podophyllotoxins, and colchicine, results 
in the development of cross-resistance to other mem- 
bers of the MDR drug family. These MDR-related 
drugs are structurally dissimilar and have different 
intracellular targets. What these drugs have in 
common is that they are, in general, rather large 
(between 300 and 900 MW), hydrophobic, enter 
the cell by passive diffusion, and have affinity for 
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P-glycoprotein. Classical MDR cells are not cross- 
resistant to alkylating agents (e.g. chlorambucil and 
cyclophosphamide), antimetabolites (for example, 
cytarabine, methotrexate and 5-fluorouracil), or cis- 
platin. 
P-glycoprotein appeared to be a normal membrane 
constituent incertain cell types, and expression is not 
only found in drug resistant in vitro cell lines but also 
in normal tissues with excretory functions like liver, 
kidneys, and colon [23], suggesting that it plays a 
role in the process of detoxification of the organism. 
However, P-glycoprotein s also clearly expressed in
the adrenal glands, in the endometrium of the gravid 
uterus and in the human placental trophoblast, indi- 
cating that the molecule has a normal physiological 
function, e.g. in steroid hormone transport. Over 
the years, a large number of other non-cytotoxic 
compounds, including calcium channel blockers and 
calmodulin inhibitors, has been found, which can 
also serve as substrates for the P-glycoprotein drug 
pump, and thereby circumvent drug resistance. The 
current hypothesis on the mode of action of these so- 
called resistance modifying agents (RMA) is that 
they correct he defect cytotoxic drug accumulation 
in MDR cells by competing for outward transport 
directly by binding with P-glycoprotein [24], although 
it must be emphasized that the unusually broad sub- 
strate specificity of P-glycoprotein still constitutes an 
academic problem. 
It is a very likely (and testable) hypothesis that the 
clinical observation of resistance to multidrug-based 
chemotherapy of haematological malignancies is due 
to enhanced P-glycoprotein expression i  the resist- 
ant cells. MDR-related cytotoxic drugs (anthra- 
cyclines, vinca alkaloids, and podophyllotoxins) are 
among the most active agents in the treatment of 
haematological malignancies. In these cancers, a 
relapse of resistant disease is frequently followed 
after a period of complete remission (CR). 
P-glycoprotein expression i  haematological 
malignancies 
Elevated P-glycoprotein levels and/or mdrl/P- 
glycoprotein mRNA transcript levels have been 
reported in almost all types of haematological malig- 
nancies, either untreated or treated, with expression 
levels ranging from low to high. A variety of different 
techniques have been used in the studies on the 
expression of P-glycoprotein and its mRNA in human 
haemopoietic neoplasms, all with their specific 
advantages and disadvantages [25]. Several mono- 
clonal antibodies (MoAb) directed against P-gly- 
coprotein epitopes and P-glycoprotein-specific 
nucleic acid probes are available, respectively, for 
immunocytochemistry andWestern blotting for the 
detection of the protein, and Northern- and slot 
blotting, RNase protection and polymerase chain 
reaction for the detection of its mRNA. All these 
techniques have been worked out using in vitro MDR 
model systems with abundant P-glycoprotein 
expression. In contrast, relatively low expression 
levels might be anticipated, and are actually found 
in clinical samples, a fact that beyond doubt has 
contributed tocontradictory findings in the literature. 
Another point of consideration is the specificity of 
the probes for the detection of P-glycoprotein or its 
mRNA. As alluded to earlier, in humans two mdr 
genes (mdrl and mdr3) with a high degree of hom- 
ology have been identified, each coding for a gly- 
coprotein [22]. Using mdrl- and mdr3-specific nucleic 
acid probes we have found that the mdr3 gene is 
specifically expressed in B-cell leukaemias and lym- 
phomas [26-29]. Since not all MoAbs used in studies 
on P-glycoprotein expression i  clinical samples are 
specific for the P-glycoprotein encoded by the mdrl 
gene (for example, the MoAb C219), and for some 
nucleic acid probes it has not been documented 
whether they are rndrl/P-glycoprotein mRNA- 
specific, it is theoretically possible that in B-cell leu- 
kaemias and lymphomas, P-glycoprotein expression 
levels have been overestimated, because of the lack 
of specificity. 
Ma et al. [30] were the first who reported P-gly- 
coprotein expression i two adult patients with acute 
myelocytic leukaemia (AML) by immunocyto- 
chemical assay using the MoAb C219, developed by 
Ling's group. P-glycoprotein staining could not 
be detected in the leukaemic ells at first clinical 
admission. However, as the patients relapsed after 
three or four courses of combined chemotherapy 
containing daunorubicin, C219 positive leukaemic 
cells appeared in the peripheral blood (PB). The 
proportion of positive staining cells and the intensity 
of staining increased as the disease progressed. The 
study of Ma et al. [30] had been initiated by Bell et 
al., who had successfully applied the same MoAb 
earlier in an ovarian carcinoma study [31], and ush- 
ered in a period of large scale screening for P-gly- 
coprotein expression in all kinds of haematological 
malignancies. Reports appeared on elevated P-gly- 
coprotein or mdrl/P-glycoprotein mRNA levels in 
AML [27,32-34], acute lymphocytic leukaemia 
(ALL) [27, 32, 35, 36], myelodysplastic syndromes 
(MDS) [33], chronic myelocytic leukaemia (CML) 
[27, 32, 37], chronic lymphocytic leukaemia (CLL) 
[26, 38, 39], hairy cell leukaemia [28], multiple myel- 
oma (MM) [40-42], non-Hodgkin's lymphomas 
(NHL) [43-45], as detected by immunocytochem- 
istry, slot blot analysis, or RNase protection assay. 
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From the studies that used in situ methods (immu- 
nocytochemistry or in situ RNA hybridization) for 
the detection of P-glycoprotein expression, it became 
apparent hat the leukaemic ell population can be 
very heterogeneous, with several distinct populations 
expressing high, moderate, or no P-glycoprotein 
expression, clearly demonstrating a limitation of 
the assays on RNA isolated from the total leukaemic 
cell population. The clinical implication of the 
heterogeneity in P-glycoprotein expression in the 
tumour cell population would be selection of the P- 
glycoprotein-expressing cell clones following treat- 
ment with MDR-related rugs. Indeed, evidence for 
selection of pre-existing MDR clones can be found in 
those malignancies for which the standard protocols 
contain MDR-related drugs, in, for example, adult 
AML. Although elevated P-glycoprotein expression 
levels are frequently observed in AML at diagnosis, 
the expression i treated AML patients with resistant 
disease (RD) is generally higher, as quantitated by 
analyis of RNA isolated from the total leukaemic ell 
population [27, 46-48] as well as at the single cell 
level by immunocytochemistry [30, 48]. Comparable 
evidence for selection has also been provided for 
MM: higher incidence of P-glycoprotein expression 
in patients treated with the VAD (vincristine, 
doxorubicin, dexamethasone)-protocol than in 
patients at initial presentation [49]. In the study by 
Grogan et al. [49] about a hundred MM patients were 
analysed, either before or after therapy and at the 
time of relapse. MM patients with no prior therapy 
had low incidence (6%) of P-glycoprotein expression, 
while those receiving chemotherapy with doxorubicin 
and/or vincristine had a significant higher incidence 
that was related to the cumulative drug dosages, and 
that finally became 100% at the highest cumulative 
drug levels. Typically, in a disease like CLL no clear 
evidence for selection can be found. Variable degrees 
of P-glycoprotein expression are observed in CLL at 
diagnosis, however, after the conventional treatment 
with an alkylator, with or without prednisone, agents 
that do not belong to the MDR drug family, P- 
glycoprotein expression levels appeared not to be 
related to prior therapy [27, 39]. 
Apart from selection of the MDR phenotype by 
repeated chemotherapeutic treatment, it remains 
possible that chemotherapeutic agents might them- 
selves directly induce P-glycoprotein expression at 
the transcriptional level. Evidence is accumulating 
that, at least in vitro in rodent and human cell lines, 
the mdrl/P-glyceprotein promoter can be activated 
by chemical stress-inducing agents, including cyto- 
toxic and cytostatic drugs, like vincristine, etoposide, 
daunorubicin, doxorubicin, colchicine, and hydroxy- 
urea [50-52]. If such a chemical activation of the 
mdrl/P-glycoprotein promotor also occurs in the 
patient, that would also result in increased P-gly- 
coprotein expression i the leukaemic ell population 
after chemotherapy; a situation that is hardly dis- 
cernible from in vivo selection. 
Origin of the MDR phenotype 
Recent studies [53-55] have shown that P-gly- 
coprotein is differentially expressed among the 
diverse haemopoietic differentiation lineages. In PB, 
granulocytes and monocytes were negative for P- 
glycoprotein, while T-cells, B-cells and NK cells were 
P-glycoprotein-positive. In bone marrow (BM), 
erythroid precursors and monocytic ells had no P- 
glycoprotein expression. The CD34 + early pro- 
genitor cells, committed progenitor cells, myeloid 
precursor cells, and early and mature B-cells were 
positive for P-glycoprotein. Consequently, P-gly- 
coprotein expression in untreated haematological 
malignancies might be determined by the expression 
in the normal haemopoietic counterparts. A cor- 
relation between P-glycoprotein expression and 
immature (CD34 +) cell phenotype has been reported 
for AML, MDS and therapy-induced AML [48, 56- 
58]. Since normal CD34 + haemopoietic progenitor 
cells have P-glycoprotein expression [53], it is 
conceivable that CD34* leukaemias develop by~ 
malignant transformation of normal CD34 + counter- 
parts. Such a correlation between P-glycoprotein 
expression and immature cell phenotype was also 
reported by List et al. [56] and Sonneveld et al. [58] 
for MDS. In the latter study [58] P-glycoprotein 
expression was investigated in patients with high-risk 
(n = 9) or low-risk (n -- 17) MDS. Patients with high- 
risk MDS have a poor prognosis owing to a high risk 
of transformation to AML which is usually resistant 
to chemotherapy. P-glycoprotein expression was 
demonstrated in CD34* BM blast cells in 14 of 17 
high-risk MDS and in two of nine low-risk MDS 
patients. About 80% of the P-glycoprotein-positive 
patients developed AML vs 20% of the P-glyco- 
protein-negative patients, providing a mechanistic 
basis for the poor chemotherapy-responsiveness of 
this form of AML. 
Before a normal cell ends up as a tumour cell, it 
has gone through a (multistage) process of malignant 
transformation. During such a process of genetic 
instability, cells gain new characteristics bymutations 
and/or alterations in gene expression. Recently, it 
was reported [59] that the promoter of the human 
mdrl/P-glycoprotein gene can be activated by the c- 
Ha-ras-1 oncogene and the p53 tumour suppressor 
gene products. The stimulatory effect of the ras gene 
product was not specific to the mdrl/P-glycoprotein 
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TABLE 1. P-GLYCOPROTEIN EXPRESSION AS A PROGNOSTIC FACTOR IN DE NOVO AML 
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Author Ref. No. No. patients 
P-glycoprotein expression 
Yes No 
CR (%) CR (%) 
Kuwazuru et al. (1990) 60 15 15 85 
Sato et al. (1990) 46 33 60 85 
Marie et al. (1991) 47 18 25 85 
Pirker et al. (1991) 61 63 55 90 
Campos et al. (1992) 57 122 30 80 
Zhou et al. (1992) 48 61 35 75 
Te Boekhorst et al. (1993) 62 52 27 72 
promoter alone, whereas a mutant p53 specifically 
stimulated the mdrl /P-g lycoprote in  promoter and 
wild-type p53 exerted specific repression. Both 
genes, p53 and ras are frequently associated with 
tumour progression, and mutations in p53 and mem- 
bers of the ras oncogene family are among the most 
frequently found genetic aberrations in human neo- 
plasms, including leukaemias. These results imply 
that P-glycoprotein expression could be activated 
during tumour progression associated with mutations 
in ras and p53. 
Does P-glycoprotein expression predict resistant 
disease? 
The answer is: yes, but only for some specific 
haematological malignancies, for example, AML and 
MM, diseases which are usually treated with MDR- 
related drugs. In these diseases, high levels of P- 
glycoprotein before treatment appear to be associ- 
ated with poor prognosis, c.q. resistant disease. In 
the case of AML the prognostic significance of P- 
glycoprotein expression-is extensively studied and 
the picture appears to be very clear. Several groups 
]46-48, 57, 60-62] have investigated the significance 
of P-glycoprotein overexpression asa prognostic fac- 
tor in de novo AML (Table 1). The overall conclusion 
from these AML studies is that P-glycoprotein 
expression at diagnosis is clearly an unfavourable 
prognostic factor for lower CR rates, refractory 
disease, early death, and shorter disease-free 
survival. In Table 1, the CR rates are shown in 
relation to P-glycoprotein expression at diagnosis in 
de nooo AML, reported by the Japanese, American 
and European clinical haemato-oncology research 
groups. In all studies the probability of obtaining a 
CR was dramatically reduced in the presence of P- 
glycoprotein and high P-glycoprotein levels could be 
correlated with RD. Crucial for such a correlation 
between CR rate and P-glycoprotein expression is 
the sensitivity of the assay for P-glycoprotein. False 
negative results owing to the insensitivity of the 
method would result in a lower CR rate in both AML 
groups, with or without P-glycoprotein expression. 
In the studies listed in Table 1 different echniques 
have been used for the detection and quantification 
of P-glycoprotein or its mRNA: immunoblotting with 
the MoAb C219 [60], Northern blotting [46], slot 
blot analysis [47, 48, 61], flow cytometry with the 
MoAb MRK16 [57, 62], or immunocytochemistry 
with C219 [48, 62]. The percentage ofP-glycoprotein- 
positive AML samples at diagnosis ranged from 40 
to 70%, irrespective of the method used, and except 
for the 15% CR rate in the P-glycoprotein-positive 
AML group of Kuwazuru et al. [60], more or less 
identical results have been obtained for the predictive 
significance of P-glycoprotein. P-glycoprotein 
expression at diagnosis could not be related to the 
FAB classification of AML [46, 57]. The two main 
drugs for remission induction (RI) in de novo stand- 
ard risk AML are an anthracycline in combination 
with cytarabine. This drug combination gives an aver- 
age overall CR rate of 70-80%. With conventional 
dose ara-C alone CR rates of 30% are obtained, a 
figure that fits within the range of CR rates obtained 
in P-glycoprotein-positive AML patients. In the 
study from Lyon [57] it was reported that elevated 
levels of P-glycoprotein leukaemia cells correlated 
with the presence of CD34 antigen, although both 
markers independently conferred a negative prog- 
nostic value. By combining both markers, CD34 and 
P-glycoprotein, it was possible to define a subgroup 
with a very poor prognosis (both markers positive, 
CR rate: 20%) and a subgroup with a very good 
prognosis (both markers negative, CR rate: 100%). 
In a recent study by our own group [62] it was shown 
by double-fluorescence labelling that P-glycoprotein 
is indeed almost exclusively expressed in CD34 ÷ 
AML blasts. In secondary AML, preceded by cyto- 
toxic exposure and/or a preleukaemic phase, the 
prognosis is considerably worse than in de novo 
AML. In these patients a poor prognosis is also 
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associated with increased expression of P-glyco- 
protein [33, 46, 47, 56, 57, 62], and with concurrent 
expression of P-glycoprotein and abnormal karyo- 
type:monosomy 7 and/or 7q-, as detected by in 
situ hybridization [62]. 
Several groups have published increased 
expression of P-glycoprotein in MM during devel- 
opment of clinical drug resistance [42, 49]. In most 
centres, the standard first line treatment for MM is 
melphalan and prednisone which produces an objec- 
tive response in about 50% of patients. Patients not 
responding or relapsing following initial treatment 
are often treated with combination chemotherapy 
containing VAD. Linsenmeyer et al. [42] reported 
that in MM, patients who failed to respond to first 
line therapy with melphalan and prednisone had 
significantly higher mdrl/P-glycoprotein mRNA 
levels than patients who responded. Since both drugs 
do not belong to the MDR drug family, the effec- 
tiveness of these drugs would not be expected to 
be impaired significantly in P-glycoprotein-positive 
tumours. The explanation for this apparent paradox 
seems to lie in coordinate increases in expression 
of other pathways involved in the detoxification of 
xenobiotics. In the same study [42] other genes (glu- 
tathione S-transferase (GST) 2 and 3) potentially of 
importance in drug resistance were investigated as 
well, and P-glycoprotein and GST2 expression, an 
enzyme with the ability to inactivate drugs such as 
melphalan [63], were significantly correlated. MM 
patients with no prior therapy had a low (6%) inci- 
dence of P-glycoprotein expression. However, in 
many untreated and meiphalan/prednisone tr ated 
MM patients, small numbers (<5%) of P-gly- 
coprotein plasma cells can be detected, as is the case 
in benign monoclonal gammopathy (MGUS) [64]. It 
is, therefore, conceivable that selection of P-gly- 
coprotein-expressing myeloma cells occurs during 
successive treatments. Indeed, the incidence of P- 
glycoprotein positive patients increased ramatically 
in MM after each course of chemotherapy with 
doxorubicin and/or vincristine [49]. Increased P- 
glycoprotein expression was observed in 60-80% of 
VAD-refractory patients, and in VAD-treated MM 
patients P-glycoprotein expression appeared to be a 
bad prognostic factor, predicting for RD [41,49]. In 
summary: in MM, P-glycoprotein expression appears 
to have no impact on chemotherapy response if 
it is found before treatment with doxorubicin or 
vincristine [65], while in VAD-treated patients it 
predicts for poor response. 
In untreated ALL the frequency of elevated 
P-glycoprotein expression ranged from 10 to 70% 
[27, 32, 35, 36, 60, 66] and a correlation between 
P-glycoprotein expression and treatment outcome 
seems to be less outspoken as in AML. Only in a few 
studies [36, 47, 60] could P-glycoprotein expression 
be linked with clinical results. In one study [47] 
increased P-glycoprotein expression could be 
detected in 40% of the ALL patients (n = 7), and 
none of them obtained a CR, vs 75% of the P- 
glycoprotein-negative patients. In another study [60] 
(n = 11), 25% of the P-glycoprotein-positive ALL 
patients obtained a CR, vs 65% of the P-gly- 
coprotein-negative patients. In a recently published 
study [36], a separation was made between adult (n = 
23) and childhood ALL (n = 36). The rate of first 
CR differed between P-glycoprotein-positive and 
-negative patients in adult ALL only (56% vs 93%); 
in the paediatric patients, P-glycoprotein-positive 
and -negative patients had exactly the same rate of 
CR (92%). Of the 16 P-glycoprotein-positive patients 
(11 children and 5 adults) who presented a first CR, 
81% relapsed, compared with 37% of the P-gly- 
coprotein-negative patients. A higher rate of relapse 
among P-glycoprotein-positive compared with P-gly- 
coprotein-negative patients was observed in adults as 
well as in children (adults 100% vs 46%; children 
73% vs 32%). Also, the survival rates were sig- 
nificantly higher in the P-glycoprotein-negative com- 
pared with P-glycoprotein-positive ALL adults and 
children. These data strongly suggest that in ALL P- 
glycoprotein might be a poor prognostic factor. 
Other leukaemias in which variable degrees of P- 
glycoprotein expression have been detected at diag- 
nosis include chronic phase CML and CML blast 
crisis [27, 67], and CLL [27, 29, 38, 39, 68]. In none 
of these studies was a prognostic significance of P- 
glycoprotein expression for response or survival 
detected. The results obtained so far for the lym- 
phomas are not yet unequivocal. In one study [69] 
P-glycoprotein expression did not decrease the like- 
lihood of response to induction chemotherapy. In
another study [44] newly diagnosed and untreated 
lymphoma patients had a very low (2%) incidence of 
P-glycoprotein expression, while previously treated 
and drug-resistant patients (64%) had detectable 
levels of P-glycoprotein, suggesting that P-gly- 
coprotein might contribute to drug resistance in lym- 
phoma. 
Circumvention of drug resistance in leukaemias, 
lymphomas and multiple myelomas 
In clinical practice, the circumvention of drug 
resistance has been attempted by several approaches. 
The widespread use of polychemotherapy, in fact is 
based on the notion that as soon as the tumour 
becomes manifest in the patient, it already harbours 
a variety of drug-resistant cell clones as a conse- 
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quence of spontaneous mutations. In the case of P- 
glycoprotein-mediated MDR one may use alternative 
drugs which cannot serve as a substrate for the P- 
glycoprotein drug pump. However, often the number 
of active drugs is very limited; for example, in AML 
treatment the use of effective non-MDR drugs is 
limited to cytarabine. Dose escalation of the drugs 
in order to achieve higher intracellular drug con- 
centrations has also been applied. However, that 
approach is hampered by a concurrent increase of 
toxicity, and, therefore, cannot be used without 
adequate stem cell support. In recent years, the atten- 
tion has focused on the use of agents which inhibit the 
P-glycoprotein-mediated efflux of cytostatic drugs. 
With this approach promising results have been 
reported in pilot studies and phase I/ I I  trials in MM, 
lymphoma nd AML patients, in which MDR-related 
cytotoxic drugs were combined with RMAs. The 
clinical efficacy of the experimental protocols was 
assessed by the occurrence of otherwise unexpected 
tumour responses; a rather subjective criterion that 
must be regarded as such. Especially, two drugs 
(verapamil and cyclosporine A) have gained much 
attention as RMAs for classical MDR; verapamil, 
because it is the archetypal RMA, of which it was 
first demonstrated that it could overcome MDR in 
model systems [70], and cyclosporine A due to its 
potency as a RMA [71, 72] in relation to its low 
(reversible) toxicity profile at the desired plasma 
concentrations. Both drugs had the advantage of a 
long clinical history of use in other applications. 
Apart from the well-known drug-specific toxicities 
associated with high plasma concentrations, the com- 
bined use of RMAs and cytotoxic drugs did not 
lead to severe dysfunction of organs of which P- 
glycoprotein is a normal constituent, like liver, kid- 
neys and colon. 
In MM, verapamil has been added to VAD in 
VAD-refractory patients [73, 74]. In these heavily 
pretreated patients ome responses were noted. Ver- 
apamil was also used in the treatment of drug-refrac- 
tory lymphoma [44] yielding an unexpected high 
percentage of CRs. The dose-limiting toxicity of the 
verapamil nfusion was cardiac dysfunction i cluding 
hypotension, congestive heart failure, and cardiac 
arrhythmia. In an excellent editorial, Chabner & 
Wilson [75] discussed some specific problems with 
the interpretation of the clinical result, encountered 
in this kind of pilot study. The main problem in such 
studies is the clinical use of the term resistance, 
because patients with recurrent disease can respond 
to retreatment with their original regimen, especially 
in NHL. We reported the first clinical application of 
cyclosporine A as a RMA, in a refractory AML 
patient [76]. In that case, the emergence of the classi- 
cal MDR phenotype was monitored uring clinical 
progression of the disease. At relapse, a decrease 
in daunorubicin accumulation by AML blasts was 
associated with elevated P-glycoprotein expression 
and a decreased in vitro sensitivity to daunorubicin. 
Intracellular daunorubicin accumulation and in vitro 
sensitivity could be completely restored by adding 
cyclosporine A to the cells. During progressive 
relapse, the patient was treated with reinduction 
therapy to which cyclosporine A was added and 
this resulted in a transient elimination of the P- 
glycoprotein-positive AML clone. In France, a large 
(n = 16) study was carried out [77] in which relapsed 
(n = 7) or refractory (n = 9) acute leukaemias were 
treated with cyclosporine A in combination with 
mitoxantrone and etoposide. This combination 
chemotherapy was effective in killing P-glycoprotein- 
expressing leukaemia cells and even two CRs were 
obtained. However, three of six respondents were P- 
glycoprotein-positive and the other three respon- 
dents P-glycoprotein-negative, obstructing a mean- 
ingful interpretation of the clinical responses. Other 
studies using cyclosporine A added to RI regimens 
in acute leukaemias with a poor prognosis are in 
progress. Using a similar approach, cyclosporine A
was administered to VAD-refractory MM patients, 
leading to several unexpected lasting responses [78]. 
Before treatment, P-glycoprotein expression could 
be detected in the myeloma cells in some of the 
patients. However, after the experimental treatment, 
in four of six patients no P-glycoprotein-positive 
plasma cells were present, suggesting that cyclo- 
sporine plus VAD is effective against P-glycoprotein- 
expressing myeloma cells. 
The dose-limiting toxicity of the cyclosporine 
infusion was musculoskeletal pain but also increased 
myelosuppression and hyperbilirubinaemia were 
noted. Hyperbilirubinaemia is a well-known side- 
effect of cyclosporine A in transplantation studies, 
and now appears to occur also in the MDR-modu- 
lation studies [77-79]. The presence of P-gly- 
coprotein on the luminal surfaces of the biliary tract 
[80] makes it likely that the increase in blood bilirubin 
during cyclosporine A treatment is due to impairment 
of the P-glycoprotein pump in the epithelial cells of 
the bile duct. Such an inhibition of the endogenous 
P-glycoprotein pump not only can lead to reduced 
bile excretion, but also to reduced biliary cytotoxic 
drug elimination, as has been shown for the MDR- 
related rug colchicine [81]. In another animal study, 
the same authors [82] found that colchicine is actively 
secreted into the urine by P-glycoprotein the proxi- 
mal renal tubes and that the administration of cyclo- 
sporine A dramatically reduced renal clearance of 
colchicine. When these phenomena (impaired biliary 
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and urinary drug excretion) also occur in patients 
(which is very likely), the combined use of cyclo- 
sporine A and cytotoxic drugs might contribute to 
altered pharmacokinetics, for example increased 
area under the plasma concentration/time curve 
(AUC) of the cytotoxic drugs, and a subsequent 
alteration in the toxicity profile [83-85]. In addition, 
pharmacokinetic changes in tissue distribution may 
also be induced by the possible haemodynamic effects 
of the RMAs themselves. Indeed, preclinical and 
clinical evidence isaccumulating that significant phar- 
macokinetic interactions can take place upon the 
simultaneous use of RMAs and cytotoxic drugs 
[83, 86-89]. In patients, anthracycline peak levels, 
terminal half-life and the volume of distribution were 
higher, whereas plasma drug clearance and the vol- 
ume of the central compartment were lower with co- 
administration of verapamil [86]. Nifedipine admin- 
istered to vincristine-treated patients decreased vin- 
cristine clearance from the body [87]. In a phase 1 
pharmacokinetic study, cyclosporine A produced 
a significant increase in VP-16 systemic exposure as 
a consequence of impaired total body clearance 
[89]. Altered pharmacokinetics (decreased total 
clearance, increased plasma AUC, and/or changes 
in tissue distribution) might, partly, explain why in 
clinical modulation studies often responses were seen 
too, in patients with drug resistant P-glycoprotein- 
negative tumours [44, 77, 78]. 
Altogether, it seems very likely that in clinical 
use RMAs might have a specific, P-glycoprotein- 
mediated effect on P-glycoprotein-expressing tumour 
cells as well as an aspecific, pharmacokinetic- 
mediated effect on both P-glycoprotein-positive and 
-negative tumour cells. New, less toxic and more 
potent RMAs, like the non-immunosuppressive 
cyclosporine analogue SDZ PSC 833 [72, 90], are 
under phase I evaluation. The overall conclusion is 
that modulation of drug resistance by non-cytotoxic 
RMAs seems promising and needs further clinical 
evaluation in prospective, randomized phase III 
trials. 
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